EADV: New data reinforce Sanofi’s innovative approach and leadership across immune-mediated skin diseases 24 abstracts for Dupixent, including 4 oral presentations, highlight impact of targeting interleukin-4 (IL4) and interleukin-13 (IL13) across atopic dermatitis (AD), prurigo nodularis (PN) and chronic spontaneous urticaria (CSU)New data show impact of Dupixent on potential for clinical remission in children as young as six years of age with moderate-to-severe AD15 abstracts for immunology pipeline molecules, including phase 2 presentations in AD for amlitelimab, an OX40-ligand monoclonal antibody Paris, September 25, 2024.

EADV：新数据加强了赛诺菲在免疫介导的皮肤病领域的创新方法和领导地位24 Dupixent摘要，包括4篇口头报告，重点介绍了针对特应性皮炎（AD），结节性痒疹（PN）和慢性自发性荨麻疹（CSU）的白细胞介素-4（IL4）和白细胞介素-13（IL13）的靶向作用。新数据显示Dupixent对6岁以下儿童临床缓解潜力的影响，中度至重度AD15免疫学管道分子摘要，包括2024年9月25日在巴黎举行的针对OX40配体单克隆抗体amlitelimab的AD第二阶段报告。

Sanofi will present 39 abstracts across approved and pipeline medicines at the 2024 European Academy of Dermatology and Venereology (EADV) medical meeting from September 25-28 in Amsterdam, the Netherlands. Presentations will include 21 abstracts for Dupixent (dupilumab) in partnership with Regeneron, highlighting the impact of targeting IL4 and IL13 across three chronic skin conditions, including disease remission data and long-term data in children with moderate-to-severe atopic dermatitis (AD), and rapid results in adults with prurigo nodularis (PN).

赛诺菲将于9月25日至28日在荷兰阿姆斯特丹举行的2024年欧洲皮肤病和性病学会（EADV）医学会议上，提交39份已批准和管道药物的摘要。演讲将包括与Regeneron合作的Dupixent（dupilumab）的21篇摘要，强调针对IL4和IL13在三种慢性皮肤病中的影响，包括中度至重度特应性皮炎（AD）儿童的疾病缓解数据和长期数据，以及结节性痒疹（PN）成人的快速结果。

In addition, data presentations from Sanofi’s extensive immunology pipeline include oral and poster presentations for amlitelimab, an OX40-ligand monoclonal antibody, demonstrating safety and efficacy results in moderate-to-severe AD, as well as in poster presentations for rilzabrutinib, a novel oral BTK inhibitor, showing its impact on symptoms of AD and moderate-to-severe chronic spontaneous urticaria (CSU).

此外，赛诺菲广泛的免疫学渠道的数据展示包括OX40配体单克隆抗体amlitelimab的口服和海报展示，证明了中度至重度AD的安全性和有效性，以及新型口服BTK抑制剂rilzabrutinib的海报展示，显示其对AD症状和中度至重度慢性自发性荨麻疹（CSU）的影响。

Dietmar Berger, M.D., Ph.D. Chief Medical Officer, Global Head of Development at Sanofi “Our data at EADV highlight the breadth of our diverse and novel approach across inflammatory dermatolo.

Dietmar Berger，医学博士，首席医学官，赛诺菲全球发展总监“我们在EADV的数据突出了我们在炎症性皮肤病中多样化和新颖的方法的广度。

Attachment

附件

Media Update

媒体更新

Share

分享